231 related articles for article (PubMed ID: 15174306)
21. Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts.
Molina J; Martins-Filho O; Brener Z; Romanha AJ; Loebenberg D; Urbina JA
Antimicrob Agents Chemother; 2000 Jan; 44(1):150-5. PubMed ID: 10602737
[TBL] [Abstract][Full Text] [Related]
22. Effects of nitroheterocyclic drugs on macromolecule synthesis and degradation in Trypanosoma cruzi.
Goijman SG; Stoppani AO
Biochem Pharmacol; 1985 Apr; 34(8):1331-6. PubMed ID: 2581582
[TBL] [Abstract][Full Text] [Related]
23. Indazoles: a new top seed structure in the search of efficient drugs against Trypanosoma cruzi.
Aguilera-Venegas B; Olea-Azar C; Arán VJ; Speisky H
Future Med Chem; 2013 Oct; 5(15):1843-59. PubMed ID: 24144415
[TBL] [Abstract][Full Text] [Related]
24. Microsatellite and mini-exon analysis of Mexican human DTU I Trypanosoma cruzi strains and their susceptibility to nifurtimox and benznidazole.
Martínez I; Nogueda B; Martínez-Hernández F; Espinoza B
Vector Borne Zoonotic Dis; 2013 Mar; 13(3):181-7. PubMed ID: 23421890
[TBL] [Abstract][Full Text] [Related]
25. Drug resistance in Trypanosoma cruzi is not associated with amplification or overexpression of P-glycoprotein (PGP) genes.
Murta SM; dos Santos WG; Anacleto C; Nirdé P; Moreira ES; Romanha AJ
Mol Biochem Parasitol; 2001 Oct; 117(2):223-8. PubMed ID: 11606233
[No Abstract] [Full Text] [Related]
26. [Different effects of nifurtimox and benznidazole on the biosynthesis of DNA, RNA and proteins in Trypanosoma cruzi].
Goijman SG; Frasch AC; Stoppani AO
Medicina (B Aires); 1984; 44(3):261-70. PubMed ID: 6085847
[No Abstract] [Full Text] [Related]
27. Biochemical behavior of Trypanosoma cruzi strains isolated from mice submitted to specific chemotherapy.
Marretto JP; Andrade SG
Rev Soc Bras Med Trop; 1994; 27(4):209-15. PubMed ID: 7855362
[TBL] [Abstract][Full Text] [Related]
28. Intracellular growth and metacyclogenesis defects in Trypanosoma cruzi carrying a targeted deletion of a Tc52 protein-encoding allele.
Allaoui A; François C; Zemzoumi K; Guilvard E; Ouaissi A
Mol Microbiol; 1999 Jun; 32(6):1273-86. PubMed ID: 10383767
[TBL] [Abstract][Full Text] [Related]
29. Damage of Trypanosoma cruzi deoxyribonucleic acid by nitroheterocyclic drugs.
Goijman SG; Frasch AC; Stoppani AO
Biochem Pharmacol; 1985 May; 34(9):1457-61. PubMed ID: 3888226
[TBL] [Abstract][Full Text] [Related]
30. Trypanosoma cruzi: effect and mode of action of nitroimidazole and nitrofuran derivatives.
Maya JD; Bollo S; Nuñez-Vergara LJ; Squella JA; Repetto Y; Morello A; Périé J; Chauvière G
Biochem Pharmacol; 2003 Mar; 65(6):999-1006. PubMed ID: 12623132
[TBL] [Abstract][Full Text] [Related]
31. Mechanism of action of a nitroimidazole-thiadiazole derivate upon Trypanosoma cruzi tissue culture amastigotes.
de Castro SL; Meirelles Mde N
Mem Inst Oswaldo Cruz; 1990; 85(1):95-9. PubMed ID: 2215238
[TBL] [Abstract][Full Text] [Related]
32. Current drug therapy and pharmaceutical challenges for Chagas disease.
Bermudez J; Davies C; Simonazzi A; Real JP; Palma S
Acta Trop; 2016 Apr; 156():1-16. PubMed ID: 26747009
[TBL] [Abstract][Full Text] [Related]
33. A cysteine protease inhibitor cures Chagas' disease in an immunodeficient-mouse model of infection.
Doyle PS; Zhou YM; Engel JC; McKerrow JH
Antimicrob Agents Chemother; 2007 Nov; 51(11):3932-9. PubMed ID: 17698625
[TBL] [Abstract][Full Text] [Related]
34. In vitro and in vivo trypanocidal activity of the ethyl esters of N-allyl and N-propyl oxamates using different Trypanosoma cruzi strains.
Aguirre-Alvarado C; Zaragoza-Martínez F; Rodríguez-Páez L; Nogueda B; Baeza I; Wong C
J Enzyme Inhib Med Chem; 2007 Apr; 22(2):227-33. PubMed ID: 17518350
[TBL] [Abstract][Full Text] [Related]
35. Altered expression of cruzipain and a cathepsin B-like target in a Trypanosoma cruzi cell line displaying resistance to synthetic inhibitors of cysteine-proteinases.
Yong V; Schmitz V; Vannier-Santos MA; de Lima AP; Lalmanach G; Juliano L; Gauthier F; Scharfstein J
Mol Biochem Parasitol; 2000 Jun; 109(1):47-59. PubMed ID: 10924756
[TBL] [Abstract][Full Text] [Related]
36. Lectin receptors distribution in the surface membrane of Trypanosoma cruzi blood forms collected from mice submitted to specific treatment.
Fontes G; Romanha AJ; Pereira ME; Brener Z
Mem Inst Oswaldo Cruz; 1991; 86(3):297-9. PubMed ID: 1842420
[TBL] [Abstract][Full Text] [Related]
37. Acute Chagas outbreaks: molecular and biological features of Trypanosoma cruzi isolates, and clinical aspects of acute cases in Santander, Colombia.
Díaz ML; Leal S; Mantilla JC; Molina-Berríos A; López-Muñoz R; Solari A; Escobar P; González Rugeles CI
Parasit Vectors; 2015 Nov; 8():608. PubMed ID: 26612724
[TBL] [Abstract][Full Text] [Related]
38. Comparative studies of drug susceptibility of five strains of Trypanosoma cruzi in vivo and in vitro.
Neal RA; van Bueren J
Trans R Soc Trop Med Hyg; 1988; 82(5):709-14. PubMed ID: 3075357
[TBL] [Abstract][Full Text] [Related]
39. In vitro susceptibility of Trypanosoma cruzi strains from Santander, Colombia, to hexadecylphosphocholine (miltefosine), nifurtimox and benznidazole.
Luna KP; Hernández IP; Rueda CM; Zorro MM; Croft SL; Escobar P
Biomedica; 2009 Sep; 29(3):448-55. PubMed ID: 20436996
[TBL] [Abstract][Full Text] [Related]
40. Trypanothione Reductase: A Target for the Development of Anti- Trypanosoma cruzi Drugs.
Vázquez K; Paulino M; Salas CO; Zarate-Ramos JJ; Vera B; Rivera G
Mini Rev Med Chem; 2017; 17(11):939-946. PubMed ID: 28302040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
